Baricitinib - Eli Lilly/Incyte Corporation

Drug Profile

Baricitinib - Eli Lilly/Incyte Corporation

Alternative Names: INCB-028050; INCB-28050; LY-3009104; Olumiant

Latest Information Update: 05 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Incyte Corporation
  • Developer Eli Lilly; Incyte Corporation
  • Class Acetonitriles; Antipsoriatics; Antirheumatics; Azetidines; Pyrazoles; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Rheumatoid arthritis
  • Phase III Atopic dermatitis; Systemic lupus erythematosus
  • Phase II Giant cell arteritis
  • Clinical Phase Unknown Psoriatic arthritis
  • Discontinued Diabetic nephropathies; Psoriasis

Most Recent Events

  • 25 Sep 2018 Eli Lilly initiates enrolment in a phase III trial for Atopic dermatitis (Combination therapy) in Spain (EudraCT2018-001726-26)
  • 02 Aug 2018 Eli Lilly and Incyte Corporation initiates the phase III BRAVE II trial for Systemic lupus erythematosus in USA (PO) (NCT03616964)
  • 02 Aug 2018 Phase-III clinical trials in Systemic lupus erythematosus in USA (PO) (NCT03616912)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top